Advertisement

Role of TGF-β1, its receptor TGFβRII, and Smad proteins in the progression of colorectal cancer

  • Maya GulubovaEmail author
  • Irena Manolova
  • Julian Ananiev
  • Alexander Julianov
  • Yovcho Yovchev
  • Katya Peeva
Original Article

Abstract

Aim

In the current study, we investigated the expression of TGF-β1, its receptor TGFβRII, and the signaling proteins Smad4 and Smad7 in colorectal cancer tissue in relation to infiltration with antigen-presenting cells and some clinical and pathologic parameters of disease progression in patients with colorectal cancer (CRC).

Materials and methods

The immunohistochemical expression of TGF-β1, TGFβRII, Smad4, Smad7, HLA-DR antigen, CD1a, CD83, and CD68 was evaluated in 142 patients (50 females and 92 males) with CRC, followed-up for 6–8 years period.

Results

In our study, 127 (89.4%) out of 142 colorectal cancers displayed cytoplasmic TGF-β1 immunoreactivity. Common-mediator Smad4 was detected in the tumor cytoplasm in 124 cancers (79.5%) and inhibitory Smad7 immunostaining was observed in 110 (77.4%) tumor specimens. TGFβRII was expressed on tumor cell membranes in 119 (76.3%) of the cancers. The increased TGF-β1 expression in tumor cytoplasm was related to low CD68+- and CD83+-cell infiltration in tumor tissues. Patients with TGF-β1 overexpression had worse prognosis after surgical therapy compared to those with low expression of TGF-β1. The observed association was more pronounced for the patients in T1–T2 stage (p = 0.0015).

Conclusions

The expression of TGF-β1, its receptor TGFβRII, and signaling proteins Smad4 and Smad7 was observed in the majority of colorectal cancer specimens. Our results suggest that TGF-β1 production by tumor cells may affect the tumor environment via suppression of tumor-infiltrating immune cells and probably contributes to tumor cells aggressiveness through autocrine activation of Smad signaling.

Keywords

Colorectal cancer TGF-β TGFβRII Smad proteins Dendritic cells Macrophages 

References

  1. 1.
    Baker K, Chong G, Foulkes WD, Jass JR (2006) Transforming growth factor-beta pathway disruption and infiltration of colorectal cancers by intraepithelial lymphocytes. Histopathology 49:371–380CrossRefPubMedGoogle Scholar
  2. 2.
    Korchynskyi O, Landstrom M, Stoika R, Funa K, Heldin C-H, ten Dijke P, Souchelnytskyi S (1999) Expression of Smad proteins in human colorectal cancer. Int J Cancer 82:197–202CrossRefPubMedGoogle Scholar
  3. 3.
    Elliot RL, Blobe GC (2005) Role of transforming growth factor beta in human cancer. J Clin Oncol 23:2078–2093CrossRefGoogle Scholar
  4. 4.
    Bacman D, Merkel S, Croner R, Papadopoulos T, Brueckl W, Dimmler A (2007) TGF-beta receptor downregulation in tumor-associated stroma worsens prognosis and high-grade tumours show more tumour-associated macrophages and lower TGF-beta1 expression in colon carcinoma: a retrospective study. BMC Cancer 7:156–166CrossRefPubMedGoogle Scholar
  5. 5.
    Xu Y, Pashe B (2007) TGF-β signaling alterations and susceptibility to colorectal cancer. Hum Mol Genet 16(SPEC1):R14-R20. doi: 10.1093/hmg/dd1486
  6. 6.
    Heldin C-H, Miyazono K, ten Duke P (1997) TGF- β signaling from cell membrane to nucleus via Smad proteins. Nature 390:465–471CrossRefPubMedGoogle Scholar
  7. 7.
    Derynck R, Feng X-H (1997) TGF- β receptor signaling. Biochim Biophys Acta 1333:F105–F150PubMedGoogle Scholar
  8. 8.
    Engle SJ, Hoying JB, Boivin GP, Ormsby I, Gartside PS, Doetschman T (1999) Transforming growth factor β1 suppresses nonmetastatic colon cancer at an early stage of tumorigenesis. Cancer Res 59:3379–3386PubMedGoogle Scholar
  9. 9.
    Friedman E, Gold LI, Klimstra D, Zeng ZS, Winawer S, Cohen A (1995) High levels of transforming growth factor beta 1 correlate with disease progression in human colon cancer. Cancer Epidemiol Biomarkers Prev 4:549–554PubMedGoogle Scholar
  10. 10.
    Robson H, Anderson E, James RD, Schofield PF (1996) Transforming growth factor beta 1 expression in human colorectal tumors: an independent prognostic marker in a subgroup of poor prognosis patients. Br J Cancer 74:753–758PubMedGoogle Scholar
  11. 11.
    Shibahara T, Si-Tahar M, Shaw SK, Madara JL (2000) Adhesion molecules expressed on homing lymphocytes in model intestinal epithelia. Gastroenterology 118:289–298CrossRefPubMedGoogle Scholar
  12. 12.
    Reinacher-Schick A, Baldus SE, Romdhana B, Landsberg S, Zapatka M, Monig SP, Holscher AH, Dienes HP, Schmiegel W, Schwarte-Waldhoff I (2004) Loss of Smad4 correlates with loss of the invasion suppressor E-cadherin in advanced colorectal carcinomas. J Pathol 202:412–420CrossRefPubMedGoogle Scholar
  13. 13.
    Bates RC, Mercurio AM (2005) The epithelial-mesenchymal transition (EMT) and colorectal cancer progression. Cancer Biol Ther 4:365–370PubMedCrossRefGoogle Scholar
  14. 14.
    Talmadge JE, Donkor M, Scholar E (2007) Inflammatory cell infiltration of tumors: Jekyll or Hyde. Cancer Metast Rev 26:373–400CrossRefGoogle Scholar
  15. 15.
    NakayamaY NN, Minagawa N, Inoue Y, Katsuki T, Onitsuka K, Sako T, Hirata K, Nagata N, Itoh H (2002) Relationships between tumor-associated macrophages and clinicopathological factors in patients with colorectal cancer. Anticancer Res 22:4291–4296Google Scholar
  16. 16.
    Shurin MR, Shurin GV, Lokshin A, Yurkovetsky Z, Gutkin DW, Chatta G, Zhong H, Han B, Ferris RL (2006) Intratumoral cytokines/chemokines/growth factors and tumor infiltrating dendritic cells: friends or enemies? Cancer Metastasis Rev 25:333–356CrossRefPubMedGoogle Scholar
  17. 17.
    Miygawa S, Soeda J, Takagi S, Miwa S, Ichikawa E, Noike T (2004) Prognostic significance of mature dendritic cells and factors associated with their accumulation in metastatic liver tumors from colorectal cancer. Hum Pathol 35:1392–1396CrossRefGoogle Scholar
  18. 18.
    Gulubova М, Manolova I, Cirovski G, Sivrev D (2008) Recruitment of dendritic cells in human liver with metastases. Clin Exp Metast 25:777–785CrossRefGoogle Scholar
  19. 19.
    UICC. TNM Classification of Malignant Tumours 6th ed (2002) In: Sobin LH, Wittekind Ch (eds) Wiley-Liss, New YorkGoogle Scholar
  20. 20.
    Kioshima T, Kobayashi I, Matsuo K, Ishibashi Y, Miyoshi A, Akashi Y, Sakai H (1998) Immunohistochemical localization of laminin, collagen type IV and heparan sulfate proteoglycan in human colorectal adenocarcinoma: correlation with local invasive pattern and lymph node metastasis. Acta Histochem Cytochem 31:39–47Google Scholar
  21. 21.
    Gulubova M, Vlaykova T (2006) Immunohistochemical assessment of fibronectin and tenascin and their integrin receptors alpha5beta1 and alpha9beta1 in gastric and colorectal cancers with lymph node and liver metastases. Acta Histochem 108:25–35CrossRefPubMedGoogle Scholar
  22. 22.
    Guzinska-Ustymowicz K, Kemona A (2005) Transforming growth factor beta can be a parameter of aggressiveness of pT1 colorectal cancer. World J Gastroenterol 11:1193–1195PubMedGoogle Scholar
  23. 23.
    Von Rahden BHA, Stein HJ, Feith M, Puhringer F, Theisen J, Siewert R, Sarbia M (2006) Overexpression of TGF-β1 in esophageal (Barrett’s) adenocarcinoma is associated with advanced stage of disease and poor prognosis. Mol Carcinog 45:786–794CrossRefGoogle Scholar
  24. 24.
    Lu Y, Wu L-Q, Li C-S, Wang S-G, Han B (2008) Expression of transforming growth factors in hepatocellular carcinoma and its relations with clinicopathological parameters and prognosis. Hepatobiliary Pancreat Dis Int 7:174–178PubMedGoogle Scholar
  25. 25.
    Park YN, Chae KJ, Oh B-K, Choi J, Choi KS, Park C (2004) Expression of Smad7 in hepatocellular carcinoma and dysplastic nodules: resistance mechanism to transforming growth factor-β. Hepato-Gastroenterol 51:396–400Google Scholar
  26. 26.
    Picon A, Gold LI, Wang J, Cohen A, Friedman E (1998) A subset of metastatic human colon cancers expresses elevated levels of transforming growth factor β1. Cancer Epidemiol Biomark Prev 7:497–504Google Scholar
  27. 27.
    Chang H-L, Gillett N, Figari I, Lopez A, Palladino M, Derynck R (1993) Increased transforming growth factor β expression inhibits cell proliferation in vitro, yet increases tumorigenicity and tumor growth of Meth A sarcoma cells. Cancer Res 53:4391–4398PubMedGoogle Scholar
  28. 28.
    Shim KS, Kim KH, Han WS, Park EB (1999) Elevated serum levels of transforming growth factor- β1 in patients with colorectal carcinoma. Cancer 85:554–561CrossRefPubMedGoogle Scholar
  29. 29.
    Gold L, Saxena B, Mittalk K, Marmor M, Goswami S, Nactigal L, Kork M, Demopoulos R (1994) Increased expression of transforming growth factor β isoforms and basic fibroblast growth factor in complex hyperplasia and adenocarcinoma of the endometrium: evidence for paracrine and autocrine action. Cancer Res 54:2347–2358PubMedGoogle Scholar
  30. 30.
    Gorsch S, Memoli V, Stukel T, Gold L, Arrick B (1992) Immunohistochemical staining for transforming growth factor β1 associates with disease progression in human breast cancer. Cancer Res 52:6949–6952PubMedGoogle Scholar
  31. 31.
    Bellone G, Carbone A, Tibaudi D, Mauri F, Ferrero I, Smirne C, Suman F, Rivetti C, Migliaretti G, Camandona M, Palestro G, Emanuelli G, Rodeck U (2001) Differential expression of transforming growth factors- β1, -β2 and -β3 in human colon carcinoma. Eur J Cancer 37:224–233CrossRefPubMedGoogle Scholar
  32. 32.
    Alazzouzi H, Alhopuro P, Salovaara R, Sammalkorpi H, Jarvinen H, Mecklin J-P, Hemminki A, Schwartz S, Aaltonen L, Arango D (2005) Smad4 as a prognostic marker in colorectal cancer. Clin Cancer Res 11:2606–2611CrossRefPubMedGoogle Scholar
  33. 33.
    Isaksson-Mettavainio M, Palmqvist R, Forssell J, Stenling R, Oberg A (2006) Smad4/DPC4 expression and prognosis in human colorectal cancer. Anticancer 26:507–510Google Scholar
  34. 34.
    Javelaud D, Delmas V, Moller M, Sextius P, Andre J, Menashi S, Larue L, Mauviel A (2005) Stable verexpression of Smad7 in human melanoma cells inhibits their tumorigenicity in vitro and in vivo. Oncogene 24:7624–7629CrossRefPubMedGoogle Scholar
  35. 35.
    Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, Fan RS, Zborowska E, Kinzler KW, Vogelstein B et al (1995) Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 268:1336–1338CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Maya Gulubova
    • 1
    Email author
  • Irena Manolova
    • 2
  • Julian Ananiev
    • 1
  • Alexander Julianov
    • 3
  • Yovcho Yovchev
    • 3
  • Katya Peeva
    • 4
  1. 1.Department of General and Clinical Pathology, Medical FacultyTrakia UniversityStara ZagoraBulgaria
  2. 2.Laboratory of Clinical Immunology, Medical FacultyTrakia UniversityStara ZagoraBulgaria
  3. 3.Department of Surgery, University Hospital, Medical FacultyTrakia UniversityStara ZagoraBulgaria
  4. 4.Department of Informatics and Biostatistics, Medical FacultyTrakia UniversityStara ZagoraBulgaria

Personalised recommendations